Tags : Efficacy

Amgen Reports Safety & Efficacy Results of Repatha (evolocumab) in

Shots: The OSLER-1 (Open-Label Study of Long-TERm Evaluation Against LDL-C) study involves assessing of Repatha (420 mg) + SoC or SoC alone in patients with hypercholesterolemia in ratio (2:1) across 192 sites in 18 countries OSLER-1 (N≤ 1324) study results: reduction in mean LDL-C @1/2/3/4/5yrs. (59%, 56%, 57%, 56%, 56%). Another study GOULD is practiced in patients […]Read More